Thyroid Cancer Clinical Trial
Official title:
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
1. Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal
on metabolic profile.
2. Background and method:： The prevalence of thyroid cancer has increased in recent
decades. Patients with thyroid cancer need to choose between Thyrogen® injection and
Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective,
observational study, aiming to observe the difference of metabolic profiles between
patients choose Thyrogen® injection and Eltroxin® withdrawal.
Inclusion ： Patient number: 500人
Inclusion criteria :
1. Patients with diagnosis of thyroid cancer。
2. Patients who need radioiodine therapy or scan。
Exclusion criteria:
1. Patients cannot cooperate with blood test.。
2. Patients cannot cooperate with radioiodine therapy。 Study design： Prospective,
observational study。
Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy
during each visit (total 3 visits) and check lipid profiles, glucose profiles and
inflammation markers. We will compare the difference between results of patients undergoing
Thyrogen® injection and Eltroxin® withdrawal.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
| Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
| Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
| Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
| Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
| Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
| Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
| Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
| Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
| Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
| Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
| Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
| Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
| Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
| Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |